Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

BERKELEY, Calif. and MAINZ, Germany, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its participation as an exhibitor at the esteemed Gynecology Congress (‘Gynäkologie und Geburtshilfe aktuell’) in Stuttgart, Germany, on March 1st. This engagement signifies the company's commitment to advancing colorectal cancer (CRC) screening through their i

Related Keywords

Berkeley ,California ,United States ,Germany ,Mainz Biomed ,Anne Hennecke Caroline Bergmann ,Hershel Berry ,World Cancer Research Fund International ,Gynecology Congress Gyn ,Mc Services ,Us Preventive Services Task ,Gynecology Congress ,Blueprint Life Science Group ,Nasdaq ,Fecal Immunochemical Tests ,German Society ,Internal Medicine ,World Cancer Research Fund ,Services Task Force ,Polymerase Chain Reaction Based ,Colorectal Cancer ,The Company ,Cancer Screening ,Ynecology ,Blood In Stool ,Ainz ,Molecular Genetics ,Abiomed ,Company ,